Omeprazole (A2845): Technical Guidance for H+,K+-ATPase Inhibition Workflows

What This Product Solves

Omeprazole (SKU A2845), chemically known as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, is widely used as a potent H+,K+-ATPase inhibitor for laboratory studies focusing on gastric acid secretion and antiulcer activity. The compound enables precise modeling of proton pump inhibition and supports reproducible experiments in peptic ulcer disease research and the assessment of gastric acid-related disorders. Its specificity and purity are essential for mechanistic studies that require rigorous control over experimental variables.

Omeprazole's established IC50 values and robust physicochemical profile make it a cornerstone for in vitro studies where accurate quantification of gastric acid secretion inhibition is required. It is not intended for any diagnostic or clinical use; application is strictly limited to scientific research settings where controlled workflows and quality assurance are critical. For full specifications and ordering information, refer to Omeprazole at APExBIO.

Protocol Parameters

• Assay: H+,K+-ATPase inhibition
  Value with unit: IC50 = 5.8 μM
  Applicability: In vitro enzyme inhibition assays for proton pump studies
  Rationale: Provides a quantifiable benchmark for evaluating gastric acid secretion inhibition.
  Source type: Product information
• Assay: Histamine-induced acid formation
  Value with unit: IC50 = 0.16 μM
  Applicability: Cell-based models assessing stimulated gastric acid secretion
  Rationale: Supports mechanistic studies of histamine-triggered proton pump activity.
  Source type: Product information
• Assay: Compound solubility in DMSO
  Value with unit: ≥17.27 mg/mL
  Applicability: Stock solution preparation for screening and mechanistic assays
  Rationale: Ensures accurate dosing and reproducible delivery in in vitro workflows.
  Source type: Product information

Workflow Setup and QC Checklist

For researchers using Omeprazole in gastric acid secretion research or antiulcer activity study models, protocol execution should follow these technical recommendations:

• Store Omeprazole as a solid at -20°C. Avoid repeated freeze-thaw cycles to prevent degradation.
• Prepare stock solutions exclusively in DMSO, ensuring concentrations do not exceed solubility limits (≥17.27 mg/mL). Do not attempt dissolution in water or ethanol, as the compound is insoluble in these solvents.
• Prepare working solutions immediately prior to use. For experiments extending beyond several hours, monitor for precipitation or degradation.
• Use only research-grade consumables and maintain aseptic technique to avoid contamination, particularly in cell-based assays.
• Confirm batch purity (approximately 98%) before critical experiments. Document lot numbers and conditions for reproducibility.
• Dispose of unused solution stocks after each session; long-term storage of solutions is not recommended due to stability concerns.
• For shipping, ensure blue ice is used as specified to maintain compound integrity during transit.

For further workflow optimization, see the article "Omeprazole (A2845): Technical Guidance for Research Use", which details best practices in handling, assay setup, and avoiding stability-related errors.

Common Failure Modes and Fixes

• Precipitation in working solutions: Occurs if Omeprazole is dissolved in water or ethanol, or if DMSO concentrations exceed solubility limits. Fix: Verify solvent compatibility and freshly prepare DMSO stocks within solubility specifications.
• Loss of inhibitory activity: Common if solutions are stored long-term or exposed to repeated freeze-thaw cycles. Fix: Store only as a solid at -20°C and prepare solutions immediately before use.
• Batch-to-batch variability: Can arise from inconsistent purity or improper storage. Fix: Confirm purity and document storage/shipping conditions for each lot. Use internal QC controls where possible.
• Assay interference from vehicle: High DMSO concentrations may affect cell viability in sensitive models. Fix: Titrate DMSO content and validate vehicle controls in each assay system.

The internal article "Omeprazole (A2845): High-Purity H+,K+-ATPase Inhibitor for Mechanistic Studies" further discusses reproducibility and troubleshooting in proton pump inhibition assays.

Scope and Limitations

• Designed exclusively for in vitro and preclinical research applications involving proton pump inhibition, antiulcer activity, and gastric acid secretion studies.
• Not suitable for diagnostic, therapeutic, or clinical use. Regulatory compliance restricts application to laboratory research only.
• Cross-domain use (e.g., in non-gastric models) is not supported unless justified by experimental rationale and validated within the research context.
• Stability and solubility constraints require strict adherence to handling and preparation recommendations. Deviation can compromise assay performance.

Conclusion

Omeprazole (A2845) from APExBIO offers a standardized, high-purity resource for laboratory research on gastric acid secretion and antiulcer mechanisms. Its clearly defined IC50 values, solubility profile, and stringent QC requirements support accurate, reproducible workflows in peptic ulcer disease modeling and related studies. For detailed specifications and additional guidance, consult the Omeprazole product page and referenced internal articles. Adherence to recommended protocols is essential for maximizing research reliability and minimizing technical error.